

# Isis E Fernandez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12070749/publications.pdf>

Version: 2024-02-01

29  
papers

3,339  
citations

430874

18  
h-index

477307

29  
g-index

31  
all docs

31  
docs citations

31  
times ranked

5606  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Impact of TGF- $\beta$ 2 on Lung Fibrosis. Proceedings of the American Thoracic Society, 2012, 9, 111-116.	3.5	530
2	Lung Volumes and Emphysema in Smokers with Interstitial Lung Abnormalities. New England Journal of Medicine, 2011, 364, 897-906.	27.0	468
3	An atlas of the aging lung mapped by single cell transcriptomics and deep tissue proteomics. Nature Communications, 2019, 10, 963.	12.8	408
4	New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet, The, 2012, 380, 680-688.	13.7	370
5	Association Between Interstitial Lung Abnormalities and All-Cause Mortality. JAMA - Journal of the American Medical Association, 2016, 315, 672.	7.4	333
6	Immune Mechanisms in Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 309-322.	2.9	245
7	Time- and compartment-resolved proteome profiling of the extracellular niche in lung injury and repair. Molecular Systems Biology, 2015, 11, 819.	7.2	211
8	Statins and Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 547-556.	5.6	133
9	Interstitial Lung Abnormalities and Reduced Exercise Capacity. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 756-762.	5.6	106
10	FK506-Binding Protein 10, a Potential Novel Drug Target for Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 455-467.	5.6	80
11	Peripheral blood myeloid-derived suppressor cells reflect disease status in idiopathic pulmonary fibrosis. European Respiratory Journal, 2016, 48, 1171-1183.	6.7	55
12	Syndecan-2 Exerts Antifibrotic Effects by Promoting Caveolin-1-mediated Transforming Growth Factor- $\beta$ 2 Receptor I Internalization and Inhibiting Transforming Growth Factor- $\beta$ 1 Signaling. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 831-841.	5.6	52
13	Pharmacokinetic and pharmacometabolomic study of pirfenidone in normal mouse tissues using high mass resolution MALDI-FTICR-mass spectrometry imaging. Histochemistry and Cell Biology, 2016, 145, 201-211.	1.7	43
14	A comparison of visual and quantitative methods to identify interstitial lung abnormalities. BMC Pulmonary Medicine, 2015, 15, 134.	2.0	39
15	Regulation of 26S Proteasome Activity in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1089-1101.	5.6	38
16	Glutathione peroxidase 3 localizes to the epithelial lining fluid and the extracellular matrix in interstitial lung disease. Scientific Reports, 2016, 6, 29952.	3.3	30
17	Pharmacometabolic response to pirfenidone in pulmonary fibrosis detected by MALDI-FTICR-MSI. European Respiratory Journal, 2018, 52, 1702314.	6.7	26
18	Single-cell RNA sequencing reveals ex vivo signatures of SARS-CoV-2-reactive T cells through "reverse phenotyping". Nature Communications, 2021, 12, 4515.	12.8	23

#	ARTICLE	IF	CITATIONS
19	Systematic phenotyping and correlation of biomarkers with lung function and histology in lung fibrosis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2016, 310, L919-L927.	2.9	21
20	Lung Adenocarcinoma Syndecan-2 Potentiates Cell Invasiveness. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2019, 60, 659-666.	2.9	20
21	Characteristic Patterns in the Fibrotic Lung. Comparing Idiopathic Pulmonary Fibrosis with Chronic Lung Allograft Dysfunction. <i>Annals of the American Thoracic Society</i> , 2015, 12, S34-S41.	3.2	16
22	The Notch ligand DNER regulates macrophage IFN $\gamma$ release in chronic obstructive pulmonary disease. <i>EBioMedicine</i> , 2019, 43, 562-575.	6.1	16
23	CX3CR1-fractalkine axis drives kinetic changes of monocytes in fibrotic interstitial lung diseases. <i>European Respiratory Journal</i> , 2020, 55, 1900460.	6.7	15
24	Proteasome activator PA200 regulates myofibroblast differentiation. <i>Scientific Reports</i> , 2019, 9, 15224.	3.3	14
25	FK506-Binding Protein 11 Is a Novel Plasma Cell-Specific Antibody Folding Catalyst with Increased Expression in Idiopathic Pulmonary Fibrosis. <i>Cells</i> , 2022, 11, 1341.	4.1	12
26	Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis. <i>PLoS ONE</i> , 2015, 10, e0136188.	2.5	11
27	Systems medicine advances in interstitial lung disease. <i>European Respiratory Review</i> , 2017, 26, 170021.	7.1	4
28	Do Circulating Monocytes Promote and Predict IPF Progression?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 9-11.	5.6	3
29	Biomarkers in Interstitial Lung Diseases. <i>Respiratory Medicine</i> , 2020, , 155-165.	0.1	2